- Electing Gail J. Maderis, a seasoned pharmaceutical executive with a strong track record of leading biopharma companies through the clinical development stage, to Opexa’s Board of Directors, thereby strengthening the Company’s oversight to execute on its key strategic initiatives;
- Appointing Mark Freedman, M.D., a leading worldwide expert in MS, to Opexa’s highly esteemed Scientific Advisory Board; and
- Advancing the clinical plans for Tovaxin and defining a clinical trial protocol for Secondary Progressive MS.
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2011 and provided an overview of recent corporate developments. Recent highlights include: